Uncategorized
This week in Drug Discovery (20-24 July 2026)
News round-up for 20-24 July by Megan Thomas, Content Team at DDW.
This week’s news roundup highlights the latest advances in cancer research and treatment, from promising clinical trial updates to discoveries that could improve the body’s immune response to tumours. The top stories include progress in therapies for breast cancer, renal cell carcinoma, sarcoma and rare cancers, alongside new research that sheds light on how the immune system organises its attack against cancer.
The top stories:
Phase II triple-negative breast cancer trial restarts
Intensity Therapeutics has administered INT230-6 in the INVINCIBLE-4 Study in Switzerland. The clinical biotechnology company is focused on the discovery and development of novel intratumoural cancer therapies that are designed to kill tumours and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology.
Allogeneic CAR-T achieves durable remissions in metastatic solid tumours
Allogene Therapeutics has announced the publication of complete Phase I data from the TRAVERSE study of ALLO-316 in advanced or metastatic renal cell carcinoma (RCC) in the Journal of Clinical Oncology.
Phase I/II trial will assess sarcoma metastatic recurrence prevention
Mirador Therapeutics has entered into an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301, a potentially long-acting, sweeping anti-C5a antibody designed to inhibit C5a/C5aR-mediated inflammation.
Cancer Research UK leads global trial of rare cancer therapy
Biotechnology company Cytovation and the Norwegian Cancer Society (NCS) have joined forces with Cancer Research UK for the trial of people with advanced adrenocortical carcinoma (ACC), a rare and aggressive cancer.
Dendritic cells found to organise cancer-fighting immune hubs
KQ Labs, led by the Francis Crick Institute and Medicines Discovery Catapult (MDC), is an annual five-month programme for early-stage companies building science-backed, scalable solutions in AI-driven drug discovery, digital health, and precision medicine.
The post This week in Drug Discovery (20-24 July 2026) appeared first on Drug Discovery World (DDW).